Clinical Trial Update: Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating safety of single or two IV doses of Orbactiv in acute bacterial skin and skin structure infections; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Skin and Skin Structure Infection

Drugs mentioned

• Orbactiv (oritavancin)

Snippet

Sponsor: The Medicines Company | Conditions: Skin Diseases, Bacterial | Phase 4 | Status: COMPLETED | Results posted: 2024-02-01